Efprezimod alfa + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19)
Trial Timeline
Apr 24, 2020 → Oct 20, 2020
NCT ID
NCT04317040About Efprezimod alfa + Placebo
Efprezimod alfa + Placebo is a phase 3 stage product being developed by Merck for Coronavirus Disease 2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04317040. Target conditions include Coronavirus Disease 2019 (COVID-19).
What happened to similar drugs?
0 of 11 similar drugs in Coronavirus Disease 2019 (COVID-19) were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04317040 | Phase 3 | Completed |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)